ArticleTuberculosis (Edinburgh, Scotland)2022
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria.
Article in Tuberculosis (Edinburgh, Scotland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Systematic and quantitative analyses of hollow fiber model ofMicrobiology spectrum · 2026Pooled it
- A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Antibiotic dose-response curves can measure antibiotic activity againstAntimicrobial agents and chemotherapy · 2026Article
- Eravacycline forMicrobiology spectrum · 2026Article
- Time Kill Curve PD Modelling Experiments Are Affected by Trailing MIC Endpoints: Refinement of MIC Determination for S. pseudintermedius.Journal of veterinary pharmacology and therapeutics · 2026Article
- Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies.The Journal of antimicrobial chemotherapy · 2026Article
- Efficacy of drug regimens containing omadacycline in a murine model ofFrontiers in microbiology · 2026Article
- Article
- Antibiotic dose-response curves can measure antibiotic activity againstbioRxiv : the preprint server for biology · 2025Article
- Luciferase reporter mycobacteriophage (TM4::Journal of clinical microbiology · 2025Article
- Repurposing drugs to advance the treatment of Buruli ulcer.Antimicrobial agents and chemotherapy · 2025Article
- Development of tetracycline analogues with increased aqueous stability for the treatment of mycobacterial infections.Tuberculosis (Edinburgh, Scotland) · 2025Article
- Tigecycline pharmacodynamics in the hollow fiber system ofFrontiers in pharmacology · 2025Article
- Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.Tuberculosis (Edinburgh, Scotland) · 2024Article
- Article
- Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- It takes two to tango! Stability of drugs affecting efficacy against Mycobacterium abscessus.International journal of antimicrobial agents · 2024Article
- Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far.The Journal of antimicrobial chemotherapy · 2024Article
- Long-term Safety and Tolerability of Omadacycline for the Treatment ofOpen forum infectious diseases · 2023Article
- Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus ActivityMicrobiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMinimum inhibitory concentration (MIC) of slow growing mycobacteria (SGM) often do not correlate with the treatment response. Among the challenges is the identification of MIC of drugs that degrade in solution faster than the doubling time of the SGM.
methodsFirst, we identified the rate of omadacycline degradation in solution, and its effect on the rapidly growing methicillin resistant Staphylococcus aureus (MRSA). We then identified doubling times versus MICs for Mycobacterium abscessus, M. avium, and M. kansasii, with and without supplementation for degraded drug.
resultsOmadacycline concentration in solution declined ∼50% over 24hr. In the MRSA experiments, omadacycline demonstrated 66.48 ± 19.38% loss in potency over 24hr, confirming the degradation rate in solution. M. abscessus had a doubling time of 8.75 ± 1.23hr and the omadacycline MIC after 24hr of incubation was 2mg/L with and without 50% daily drug supplementation, indicating that drug degradation had no effect on this rapid grower. The doubling time for M. avium was 29.52hr (95% confidence interval (CI): 23.18-33.89hr) and 31.15hr (95%CI: 19.45-38.49 hr) for M. kansasii. The M. avium MICs ±50% daily omadacycline supplementation were 1mg/L and 0.5mg/L on day 7, whereas the M. kansasii MICs ±50% daily supplementation were >128mg/L and 32mg/L on day 7.
conclusionOmadacycline degradation in solution leads to falsely high MICs when SGM doubling time exceed the drug degradation rates in solution. The challenge could be overcome by daily drug supplementation to account for the loss of potency, which is laborious, or perhaps stabilizing the drug from degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.